diff
erenti
diagnosi
sepsi
mening
broad
third
although
path
commercialis
underway
might
challeng
inexpens
straightforward
assay
excel
public
health
global
health
perspect
disrupt
new
technolog
alway
adopt
irrespect
success
commercialis
process
author
develop
novel
diagnost
test
neisseria
meningitidi
easi
use
provid
result
within
min
timefram
result
lead
action
decisionmak
like
halt
diagnost
test
nich
lamp
meningococc
diseas
remain
establish
fact
techniqu
allow
diagnost
confi
rmation
treat
hospit
rather
refer
laboratori
good
start
case
countri
arabian
peninsula
sporad
travelrel
infect
occur
elsewher
although
cluster
humantohuman
transmiss
merscov
well
document
transmiss
origin
zoonot
event
therefor
identifi
cation
anim
sourc
merscov
prioriti
genet
merscov
relat
bat
coronavirus
china
saudi
arabia
europ
africa
basi
evid
far
none
bat
countri
like
reservoir
viru
evid
accumul
dromedari
camel
natur
host
merscov
serolog
fi
nding
suggest
adult
dromedari
middl
east
africa
seroposit
merscov
viru
isol
dromedari
spike
protein
conserv
receptorbind
domain
human
dipeptidyl
receptor
merscov
detect
camel
close
contact
peopl
middl
east
respiratori
syndrom
role
camel
sourc
human
infect
middl
east
respiratori
syndrom
controversi
mani
peopl
diseas
obviou
associ
camel
casecontrol
studi
aim
defi
ne
risk
exposur
index
patient
yet
done
investig
merscov
seropreval
peopl
contact
camel
yield
neg
result
ie
associ
note
studi
muller
colleagu
fi
rst
populationbas
seroepidemiolog
investig
merscov
infect
area
zoonot
transmiss
sustain
investig
use
crosssect
design
test
serum
sampl
peopl
saudi
arabia
whose
age
sex
distribut
similar
gener
popul
use
rigor
serolog
test
algorithm
investig
identifi
ed
merscov
antibodi
ci
sampl
gener
popul
men
signifi
cantli
higher
proport
infect
women
two
infect
note
central
rural
area
coastal
provinc
vs
one
investig
also
obtain
sampl
camel
shepherd
slaughterhous
worker
show
seropreval
merscov
time
higher
camelexpos
individu
gener
popul
fi
nding
studi
suggest
young
men
saudi
arabia
contact
camel
cultur
occup
set
becom
infect
merscov
often
without
diagnos
might
proceed
introduc
viru
gener
popul
sever
ill
trigger
test
viru
diseas
recognit
hypothesi
could
account
case
middl
east
respiratori
syndrom
without
previou
anim
exposur
data
muller
colleagu
put
context
studi
camel
clearer
pictur
epidemiolog
merscov
emerg
fi
gure
camel
seem
natur
host
merscov
transmiss
within
camel
herd
well
establish
howev
sever
question
need
resolv
rout
cameltohuman
transmiss
unclear
could
one
follow
direct
contact
infect
anim
consumpt
milk
urin
uncook
meatal
practic
common
aff
ect
countri
middl
east
intermedi
host
could
also
transmit
merscov
camel
human
be
final
whether
dromedari
natur
reservoir
amplifi
er
host
hypothesi
open
investig
muller
colleagu
studi
fi
rst
step
along
way
address
question
human
papillomaviru
hpv
vaccin
programm
use
mani
countri
sinc
follow
licens
bival
quadrival
hpv
vaccin
clinic
trial
shown
hpv
vaccin
effi
caci
prevent
highgrad
cervic
lesion
caus
human
papillomaviru
type
two
hpv
type
known
caus
cervic
cancer
larg
proport
anogenit
oropharyng
cancer
quadrival
vaccin
shown
similar
effi
caci
prevent
anogenit
wart
caus
hpv
type
furthermor
vaccin
shown
lowerbut
still
substantialeffi
caci
relat
nonvaccin
oncogen
human
papillomaviru
type
therefor
sinc
rollout
vaccin
programm
began
great
anticip
see
whether
promis
trial
result
translat
substanti
reduct
hpvrelat
diseas
popul
level
lancet
infecti
diseas
drolet
colleagu
present
fi
nding
time
systemat
review
metaanalysi
assess
populationlevel
herd
eff
ect
hpv
vaccin
programm
far
key
fi
nding
studi
suggest
pretopostvaccin
period
cover
includ
studi
hpv
type
infect
anogenit
wart
decreas
girl
year
age
high
femal
vaccin
coverag
report
author
also
report
signifi
cant
reduct
hpv
type
infect
group
rel
risk
rr
ci
anogenit
wart
boy
younger
year
age
women
year
age
provid
strong
evid
crossprotect
herd
eff
ect
smaller
still
signifi
cant
reduct
hpv
type
infect
rr
ci
anogenit
wart
also
occur
girl
young
women
countri
lower
vaccin
coverag
evid
suggest
either
crossprotect
herd
immun
countri
drolet
colleagu
aim
report
populationlevel
eff
ect
vaccin
although
result
encourag
need
keep
mind
studi
includ
clinicbas
populationbas
studi
clinicbas
studi
might
repres
underli
popul
addit
vaccin
coverag
outcom
hpv
preval
base
vaccin
uptak
studi
case
substanti
larger
underli
popul
although
author
sever
subanalys
investig
heterogen
think
would
help
addit
subanalysi
stratifi
data
clinicbas
versu
populationbas
studi
disappointingli
includ
studi
highincom
countri
nine
countri
total
therefor
none
wiser
regard
eff
ect
vaccin
lowincom
countri
burden
hpvassoci
diseas
highest
report
show
maximum
populationlevel
eff
ect
vaccin
achiev
deliveri
young
age
high
vaccin
uptak
rate
result
found
strike
greatest
eff
ect
vaccin
male
femal
individu
record
countri
australia
new
zealand
uk
schoolbas
vaccin
programm
fi
nding
corrobor
result
anoth
recent
systemat
review
assess
eff
ect
quadrival
vaccin
anogenit
wart
studi
mariani
colleagu
report
greatest
reduct
anogenit
wart
achiev
countri
high
vaccin
uptak
rate
mostli
schoolbas
vaccin
programm
although
nonschoolbas
programm
also
achiev
high
vaccin
uptak
rate
one
concern
schoolbas
programm
